High-Grade Gliomas
Conditions
Keywords
Brain Tumor, Chemotherapy, Progression, Radiotherapy, Antiangiogenesis, Glioma
Brief summary
Background: * Bevacizumab is a genetically engineered antibody that blocks the growth of new blood vessels in tumors. It has shown activity against human brain tumors in laboratory tests and human clinical trials. * Irinotecan causes damage to the deoxyribonucleic acid (DNA) in cancer cells so that the cells cannot reproduce or repair themselves. It is approved for treating patients with colorectal cancer. * Bevacizumab and irinotecan in combination are more effective against colon cancer than either drug alone. Objectives: * To determine the safety of bevacizumab and irinotecan and any side effects associated with the combination of the two drugs when given to patients with high grade gliomas. * To determine if the combination of bevacizumab and irinotecan can help patients with brain tumors that have grown after treatment with bevacizumab alone. Eligibility: -Patients 18 years of age and older who have been treated on National Cancer Institute (NCI) trial 06-C-0064 (NCT00271609), Bevacizumab Alone for Recurrent Gliomas, and whose tumor has progressed. Design: Participants receive infusions of bevacizumab and irinotecan through a vein once every 2 weeks in 4-week treatment cycles, plus the following procedures: * History, physical and neurological examinations every 2 weeks for the first treatment cycle and then every 4 weeks * Magnetic Resonance Imaging (MRI) scan of the head every 4 weeks. * Routine lab every week. * Quality-of-life questionnaire every 4 weeks
Detailed description
Background: * Bevacizumab is a humanized IgG1 monoclonal antibody (MAb) that binds all biologically active isoforms of human vascular endothelial growth factor (VEGF, or VEGF-A) with high affinity (kd = 1.1 nM ). The antibody consists of a human IgG1 framework and the antigen-binding complementarity-determining regions from the murine anti-VEGF MAb A.4.6.1. * Irinotecan is a semisynthetic derivative of camptothecin that possesses greater aqueous solubility, greater in vitro and in vivo activity, and is associated with less severe and more predictable toxicity than camptothecin. * We now propose treating patients whose tumors progress on our bevacizumab alone protocol with the combination of bevacizumab with irinotecan. We believe that this trial design has significant power to detect a true synergistic effect between the two agents given that the single agent activity of irinotecan is so low in patients with recurrent malignant gliomas (2-5% response rate) and the patients being treated on this trial will have tumors that have already progressed through bevacizumab. Objective: * To establish data and safety regarding the anti-tumor activity of bevacizumab plus irinotecan in patients with recurrent high-grade gliomas that have progressed on bevacizumab alone as determined by objective radiographic response rate. * To determine the 6 month progression-free survival of treated patients and to characterize the pattern of changes in the number of endothelial progenitor cells over time and across patients. * To obtain preliminary data regarding how response to treatment (stable disease or radiographic response) effects monthly measurements of quality of life while on study. Eligibility: * Patients must have been treated on the National Cancer Institute (NCI) trial 06-C-0064; bevacizumab alone for recurrent gliomas and now have evidence for tumor progression by magnetic resonance imaging (MRI) scan. * Patients with histologically proven intracranial malignant glioma. Design: -Patients will be treated with bevacizumab by intravenous injection at a dose of 10mg/kg and irinotecan at a dose of 125 mg/m\^2 for patients on non-enzyme-inducing anti-epileptic drugs (NEIAED) and 340 mg/m\^2 for patients on enzyme-inducing anti-epileptic drugs (EIAED) every two weeks on a 4-week cycle.
Interventions
BIOLOGICALBevacizumab
10 mg/kg intravenous injection
DRUGIrinotecan hydrochloride
125 mg/m\^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m\^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: Patients must have been treated on the National Cancer Institute (NCI) trial 06-C-0064 (NCT00271609); bevacizumab alone for recurrent gliomas and now have evidence for tumor progression by magnetic resonance imaging (MRI) scan. Patients with histologically proven intracranial malignant glioma will be eligible for this protocol. Malignant glioma include glioblastoma multiforme (GBM), gliosarcoma, anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO), or malignant astrocytoma NOS (not otherwise specified). Patients must have evidence for tumor progression by MRI or computed tomography (CT) scan. This scan should be performed within 14 days prior to registration and on a fixed dose of steroids for at least 5 days. If the steroid dose is increased between the date of imaging and registration a new baseline magnetic resonance (MR)/CT is required. The same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement. Patients must be greater than or equal to 18 years old, and with a life expectancy greater than 8 weeks. All patients or their previously designated durable power of attorney (DPA) (if the patient is deemed by the treating physician to be impaired or questionably impaired in such a way that the ability of the patient to give informed consent is questionable) must sign an informed consent indicating that they are aware of the investigational nature of this study. Patients must have a Karnofsky performance status of greater than or equal to 60. Patients must not be more than 4 weeks since their last bevacizumab treatment and may have received no form of treatment (i.e. radiation, chemotherapy, surgery, investigational therapy) for their progressive tumor between their last bevacizumab treatment and enrollment of this companion trial. Patients must have adequate bone marrow function (white blood cell (WBC) greater than or equal 3,000/microl, absolute neutrophil count (ANC) greater than or equal to1,500/mm\^3, platelet count of greater than to or equal 100,000/mm\^3), and hemoglobin greater than or equal to 10 gm/dl), adequate liver function (serum glutamic oxaloacetic transaminase (SGOT) and bilirubin less than 2.5 times upper limits of normal (ULN)), and adequate renal function (creatinine less than 1.5 mg/dL and/or creatinine clearance greater than or equal to 60 cc/min) before starting therapy. These tests must be performed within 14 days prior to registration. Eligibility level for hemoglobin may be reached by transfusion. Patients must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patients' ability to tolerate this therapy. This study was designed to include women and minorities, but was not designed to measure differences of intervention effects. Males and females will be recruited with no preference to gender. No exclusion to this study will be based on race. Urine protein should be screened by dipstick or urine analysis for Urine Protein Creatinine (UPC) ratio. For proteinuria greater than or equal to 1+ or urine protein:creatinine UPC ratio greater than 1.0, 24-hour urine protein should be obtained and the level should be less than 1000 mg for patient enrollment. Subjects must be willing and able to practice adequate contraception.
Exclusion criteria
Concurrent use of other standard chemotherapeutics or investigative agents. Patients who have an active infection. Pregnant (positive pregnancy test) or nursing women. Both fertile men and women must agree to use adequate contraceptive measures during study therapy and for at least 6 months after the completion of bevacizumab therapy. Concurrent anti-coagulation or anti-platelet medication (including aspirin, non-steroidal anti-inflammatories, cyclooxygenase-2 (COX-2) inhibitors). Serious or non-healing wound, ulcer or bone fracture. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days. Invasive procedures defined as follows: * Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 therapy * Anticipation of need for major surgical procedures during the course of the study * Core biopsy within 7 days prior to day (D)1 therapy Patients with clinically significant cardiovascular disease: * History of cerebrovascular accident (CVA) within 6 months * Uncontrolled hypertension (greater than 150/100 mmHg) * Myocardial infarction or unstable angina within 6 months * New York heart association grade II or greater congestive heart failure * Serious cardiac arrhythmia requiring medication * Unstable angina pectoris * Clinically significant peripheral vascular disease Clinical evidence of bleeding diathesis or coagulopathy. Patients with known hypersensitivity of Chinese hamster ovary cell products or other recombinant human antibodies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Radiographic Response Rate (Malignant Glioma Participants) | 23 months (date of first enrollment to 1 month after last progression) | Definition of response: complete response (CR) is the complete disappearance of all measurable and evaluable disease. Partial response (PR) is greater than or equal to a 50% decrease compared to baseline in the sum of products of perpendicular diameters of all measurable lesions. Stable/No response (SD, NR)does not qualify for CR, PR, or progression. Progression is a 25% increase in the sum of products of all measurable lesions (or two target lesions if too numerous over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline. |
| Number of Participants With Toxicity as Measured by The National Cancer Institute (NCI) Common Toxicity Criteria v. 3.0. | 23 months (date of first enrollment to 1 month after last progression) | Here is the number of participants with any toxicity, defined as any adverse events possibly, probably or definitely related to the investigational drugs. For the detailed list of investigational new drug (IND)-related toxicities and other serious adverse events, see the adverse event module. |
| Radiographic Response Rate (Anaplastic Glioma Participants) | 23 months (date of first enrollment to 1 month after last progression) | Definition of response: complete response (CR) is the complete disappearance of all measurable and evaluable disease. Partial response (PR) is greater than or equal to a 50% decrease compared to baseline in the sum of products of perpendicular diameters of all measurable lesions. Stable/No response (SD, NR)does not qualify for CR, PR, or progression. Progression is a 25% increase in the sum of products of all measurable lesions (or two target lesions if too numerous over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline. |
| Radiographic Response Rate (Glioblastoma Multiforme Participants) | 23 months (date of first enrollment to 1 month after last progression) | Definition of response: complete response (CR) is the complete disappearance of all measurable and evaluable disease. Partial response (PR) is greater than or equal to a 50% decrease compared to baseline in the sum of products of perpendicular diameters of all measurable lesions. Stable/No response (SD, NR)does not qualify for CR, PR, or progression. Progression is a 25% increase in the sum of products of all measurable lesions (or two target lesions if too numerous over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Enrollment Until Prior to Treatment | 31 |
| Total | 31 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Disease Progression After Trtmt: Onstudy | Refused further treatment | 1 |
| Period1Bevacizumab & Irinotecan Patients | Disease progression before treatment | 1 |
Baseline characteristics
| Characteristic | Enrollment Until Prior to Treatment |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 30 Participants |
| Age Continuous | 46.96 years STANDARD_DEVIATION 10.39 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 30 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 29 Participants |
| Region of Enrollment United States | 31 participants |
| Sex: Female, Male Female | 12 Participants |
| Sex: Female, Male Male | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 27 / 30 |
| serious Total, serious adverse events | 9 / 30 |
Outcome results
Primary
Number of Participants With Toxicity as Measured by The National Cancer Institute (NCI) Common Toxicity Criteria v. 3.0.
Here is the number of participants with any toxicity, defined as any adverse events possibly, probably or definitely related to the investigational drugs. For the detailed list of investigational new drug (IND)-related toxicities and other serious adverse events, see the adverse event module.
Time frame: 23 months (date of first enrollment to 1 month after last progression)
Population: Analysis is per protocol (N=30), excluding the 1 patient who progressed and withdrew consent prior to any treatment but after enrollment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Enrollment Until Prior to Treatment | Number of Participants With Toxicity as Measured by The National Cancer Institute (NCI) Common Toxicity Criteria v. 3.0. | 27 Participants |
Primary
Radiographic Response Rate (Anaplastic Glioma Participants)
Definition of response: complete response (CR) is the complete disappearance of all measurable and evaluable disease. Partial response (PR) is greater than or equal to a 50% decrease compared to baseline in the sum of products of perpendicular diameters of all measurable lesions. Stable/No response (SD, NR)does not qualify for CR, PR, or progression. Progression is a 25% increase in the sum of products of all measurable lesions (or two target lesions if too numerous over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline.
Time frame: 23 months (date of first enrollment to 1 month after last progression)
Population: Analysis is per protocol (N=30), excluding the 1 patient who progressed and withdrew consent prior to any treatment but after enrollment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Enrollment Until Prior to Treatment | Radiographic Response Rate (Anaplastic Glioma Participants) | Partial response | 0 Percent of participants |
| Enrollment Until Prior to Treatment | Radiographic Response Rate (Anaplastic Glioma Participants) | Complete response | 0 Percent of participants |
| Enrollment Until Prior to Treatment | Radiographic Response Rate (Anaplastic Glioma Participants) | Stable disease | 30 Percent of participants |
| Enrollment Until Prior to Treatment | Radiographic Response Rate (Anaplastic Glioma Participants) | Progressive disease | 70 Percent of participants |
Primary
Radiographic Response Rate (Glioblastoma Multiforme Participants)
Definition of response: complete response (CR) is the complete disappearance of all measurable and evaluable disease. Partial response (PR) is greater than or equal to a 50% decrease compared to baseline in the sum of products of perpendicular diameters of all measurable lesions. Stable/No response (SD, NR)does not qualify for CR, PR, or progression. Progression is a 25% increase in the sum of products of all measurable lesions (or two target lesions if too numerous over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline.
Time frame: 23 months (date of first enrollment to 1 month after last progression)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Enrollment Until Prior to Treatment | Radiographic Response Rate (Glioblastoma Multiforme Participants) | Stable disease | 10 Percent of participants |
| Enrollment Until Prior to Treatment | Radiographic Response Rate (Glioblastoma Multiforme Participants) | Partial response | 0 Percent of participants |
| Enrollment Until Prior to Treatment | Radiographic Response Rate (Glioblastoma Multiforme Participants) | Complete response | 0 Percent of participants |
| Enrollment Until Prior to Treatment | Radiographic Response Rate (Glioblastoma Multiforme Participants) | Progressive disease | 90 Percent of participants |
Primary
Radiographic Response Rate (Malignant Glioma Participants)
Definition of response: complete response (CR) is the complete disappearance of all measurable and evaluable disease. Partial response (PR) is greater than or equal to a 50% decrease compared to baseline in the sum of products of perpendicular diameters of all measurable lesions. Stable/No response (SD, NR)does not qualify for CR, PR, or progression. Progression is a 25% increase in the sum of products of all measurable lesions (or two target lesions if too numerous over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline.
Time frame: 23 months (date of first enrollment to 1 month after last progression)
Population: Analysis is per protocol (N=30), excluding the 1 patient who progressed and withdrew consent prior to any treatment but after enrollment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Enrollment Until Prior to Treatment | Radiographic Response Rate (Malignant Glioma Participants) | Complete response | 0 Percent of participants |
| Enrollment Until Prior to Treatment | Radiographic Response Rate (Malignant Glioma Participants) | Progressive disease | 83.3 Percent of participants |
| Enrollment Until Prior to Treatment | Radiographic Response Rate (Malignant Glioma Participants) | Partial response | 0 Percent of participants |
| Enrollment Until Prior to Treatment | Radiographic Response Rate (Malignant Glioma Participants) | Stable disease | 16.7 Percent of participants |